** Shares of rare neurological disease-focused pharma company Harmony Biosciences HRMY.O up 3.7% at $35.44 premarket
** Company posts Q4 adj profit of $1.08 per share, beating analysts' estimates of 74 cents per share, according to data compiled by LSEG
** Co records Q4 sales of sleep disorder drug, Wakix, at $201.3 million, beating analysts' estimates of $200 million
** Expects 2025 net product revenue of $820 million to $860 million, midpoint of which is below analysts' estimates of $848 million
** In the last 12 months, HRMY rose 4.7%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。